In patients with type 2 diabetes and established cardiovascular disease (or in those with a high risk of cardiovascular disease) in whom glycemic goals are not achieved with metformin, agents from the GLP-1 receptor agonist or SGLT2 inhibitor classes with demonstrated cardiovascular benefit constitute the recommended treatment.
"type" - Google News
April 01, 2021 at 04:01AM
https://ift.tt/39EIP1L
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes - nejm.org
"type" - Google News
https://ift.tt/2WhN8Zg
https://ift.tt/2YrjQdq
Bagikan Berita Ini
0 Response to "Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes - nejm.org"
Post a Comment